



**HAL**  
open science

## Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes.

Aurélie C.S. Fabre, Pierre Vantourout, Eric Champagne, François Tercé, Corinne Rolland, Bertrand Perret, Xavier Collet, Ronald Barbaras, Laurent O. Martinez

### ► To cite this version:

Aurélie C.S. Fabre, Pierre Vantourout, Eric Champagne, François Tercé, Corinne Rolland, et al.. Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes.. Cellular and Molecular Life Sciences, Springer Verlag, 2006, 63 (23), pp.2829-37. 10.1007/s00018-006-6325-y . inserm-00142076

**HAL Id: inserm-00142076**

**<https://www.hal.inserm.fr/inserm-00142076>**

Submitted on 11 May 2007

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## **CELL SURFACE ADENYLATE KINASE ACTIVITY REGULATES THE F<sub>1</sub>-ATPase/P2Y<sub>13</sub>-MEDIATED HDL ENDOCYTOSIS PATHWAY ON HUMAN HEPATOCYTES**

**Aurélie C.S. Fabre, Pierre Vantourout, Eric Champagne, François Tercé, Corinne Rolland, Bertrand Perret, Xavier Collet, Ronald Barbaras, and Laurent O. Martinez.**

**INSERM, U563, Toulouse, F-31000, France,  
Université Toulouse III Paul Sabatier,  
Département Lipoprotéines et Médiateurs Lipidiques,  
Centre de Physiopathologie de Toulouse Purpan, IFR30, F-31000, France.**

Running title: Nucleotide metabolism and HDL endocytosis

Address correspondence to: Laurent O. Martinez, Hôpital Purpan, INSERM U563, Département LML Bat. C, BP 3048, 31024 Toulouse cedex 03, France.

Tel: +33 561 779 417; Fax: +33 561 779 401;

E-mail: [Laurent.Martinez@Toulouse.inserm.fr](mailto:Laurent.Martinez@Toulouse.inserm.fr).

## Abstract

We have previously demonstrated on human hepatocytes that apolipoprotein A-I binding to an ecto-F<sub>1</sub>-ATPase stimulates the production of extracellular ADP that activates a P2Y<sub>13</sub>-mediated HDL endocytosis pathway. Therefore, we investigated the mechanisms controlling extracellular ATP/ADP level on hepatic cell lines and primary cultures to determine their impact on HDL endocytosis.

Here we show that addition of ADP in the cell culture medium induced extracellular ATP production that was due to adenylate kinase (AK:  $2\text{ADP} \rightleftharpoons \text{ATP} + \text{AMP}$ ) and nucleoside diphosphokinase (NDPK:  $\text{ADP} + \text{NTP} \rightleftharpoons \text{ATP} + \text{NDP}$ ) activities, but not to ATP synthase activity. We further observed that *in vitro* modulation of both ecto-NDPK and AK activities could regulate the ADP-dependant HDL endocytosis. But interestingly, only AK appeared to naturally participate to the pathway by consuming the ADP generated by the ecto-F<sub>1</sub>-ATPase. Thus controlling extracellular ADP level is a potential target for reverse cholesterol transport regulation.

**Key words:** High Density Lipoprotein (HDL), Apolipoprotein A-I, cholesterol, hepatocytes, nucleotide metabolism, adenylate kinase, nucleoside diphosphokinase.

Cell surface receptors for high density lipoprotein (HDL) on hepatocytes are major partners in the regulation of cholesterol homeostasis [1]. We have previously identified on the cell surface of human hepatocytes a complex related to the mitochondrial ATP synthase, as a high affinity receptor for HDL apolipoprotein A-I (apoA-I) [2]. In an attempt to characterize the enzymatic activity of this cell surface ATP synthase, we uncovered that the complex could display an ATP hydrolase activity but could not synthesize ATP. We further elucidated a cell surface signalization pathway for HDL endocytosis in which apoA-I binding to the ATP synthase (namely ecto-F<sub>1</sub>-ATPase) stimulates extracellular ATP hydrolysis and the generated ADP selectively activates the nucleotide receptor P2Y<sub>13</sub> and subsequent low-affinity-receptor-dependent HDL endocytosis [2, 3]. Strikingly, the ecto-F<sub>1</sub>-ATPase activity (ATP → ADP + Pi) provides a potent P2Y<sub>13</sub> receptor agonist (i.e. ADP) and confers to the ecto-F<sub>1</sub>-ATPase its ability to stimulate HDL endocytosis. On the opposite, through degradation of extracellular ATP to adenosine, ecto-nucleotidases remove the potential to activate P2Y receptor [4]. This characteristic of ecto-nucleotidases can be revealed using the ATP/ADPase apyrase, which mimics ecto-nucleotidase activity and inhibits HDL endocytosis by hepatocytes [2]. Therefore, adenine nucleotide metabolism in the extracellular environment of hepatocytes is likely to be important for the F<sub>1</sub>-ATPase/P2Y<sub>13</sub>-mediated HDL endocytosis. Besides ecto-nucleotidases, nucleotide-converting enzymes such as the adenylate kinase (AK: 2ADP ⇌ ATP + AMP) and nucleoside diphosphokinase (NDPK: ADP + NTP ⇌ ATP + NDP) are important ADP-consuming/generating enzymes and therefore may potentially regulate the F<sub>1</sub>-ATPase/P2Y<sub>13</sub>-mediated HDL endocytosis. Although the presence and activities of such nucleotide-converting enzymes have previously been identified on the surface of different cell types [5-8], they has never been studied at the cell surface of hepatocytes.

In this study, we have identified both AK and NDPK activities at the cell surface of HepG<sub>2</sub> hepatocarcinoma cells and primary human hepatocytes. These activities participate, in concert with the ecto-F<sub>1</sub>-ATPase, in the interconversion of extracellular adenine nucleotides. In this context, we have observed that both ecto-NDPK and AK activities could act on HDL endocytosis by modulating ADP extracellular level. Interestingly, NDPK is unlikely to be constitutively active on human hepatocytes but the endogenous ADP-consuming activity of AK (2ADP → ATP +

AMP) appears to downregulate the ecto-F<sub>1</sub>-ATPase/P2Y<sub>13</sub> mediated HDL endocytosis pathway.

## Materials and Methods

*Materials* - Radiolabelled nucleotides were obtained from PerkinElmer and <sup>125</sup>I Na from GE-healthcare. The human hepatoblastoma-derived cell line HepG<sub>2</sub> was obtained from the American Type Culture Collection (HB-8065) and was cultured on Collagen I-coated plates (BD Biosciences) in high glucose DMEM supplemented with 10% foetal bovine serum and antibiotics as previously described [9]. All cell culture reagents were from Invitrogen (France). Anti-NDPK (Nm23-H1) antibody was purchased from Insight Biotechnology. Nucleotides, diadenosine pentaphosphate (Ap<sub>5</sub>A), apyrase type VII and all other reagents (analytical grade) were from Sigma (La Verpilliere, France). Ap<sub>5</sub>A was treated with 20 units/ml grade VII apyrase for 2h to hydrolyse contaminating ADP and ATP and apyrase was then inactivated by heat-treatment at 100°C for 10 min. ATP was then added to Ap<sub>5</sub>A-treated samples and luciferin-luciferase bioluminescence assay was performed to ensure that apyrase activity had been inactivated. Primary cultures of adult normal human hepatocytes have been kindly provided by the group of P. Maurel (INSERM U128, Montpellier, France) and prepared as previously described [10].

*ATP measurement by Bioluminescence Assay* -HepG<sub>2</sub> cells were seeded on 24-well plates at 75,000 cells/well (~ 60 % confluence) and allowed to adhere and grow for 48h then plates were washed and equilibrated in either 10% foetal bovine serum or serum free-DMEM without red phenol for 1 hour. Cells were then treated with different nucleotides or nucleotides analogues for 1 min. Supernatants were removed and centrifuged. For the experiments performed in 10% foetal bovine serum, serum proteins were removed from the cellular supernatants by chloroform extraction (1/1, v/v) before assaying ATP production on the upper phase of the extract. Aliquot (100 µl) of cellular supernatants were analyzed using the ATP bioluminescence assay kit CLS II (Roche Diagnostics, Basel, Switzerland). Samples were added to the ATP assay mixture and luminescence was measured in a microplate luminometer Orion

(Berthold detection systems) over a 15-s period. The ATP standard curve was performed in the same medium than the samples and in the  $10^{-5}$  to  $10^{-10}$  M concentration range. In order to monitor the number of cells in each well, adherent viable cells were lysed in NaOH 0.1M and pH-equilibrated to 7.4 with HCl 1M. Cellular protein concentration was then determined using the Bio-Rad protein assay dye and BSA as a standard. Data are expressed as picomoles of ATP produced per mg of cell proteins and the corresponding ATP molar concentrations have been specified in the result section when required.

*Dual-Label HPLC analysis* - Nucleotides were separated by HPLC through PartiSphere SAX column (Whatman, Cluzeau info lab, Saint Foy La Grande, France) and quantified on a continuous flow in-line scintillation detector (Parkard 500TR) as previously described [11]. The elution positions were determined by using appropriate standards. No ATP was detectable in the [ $^3$ H]ADP preparation used in all experiments.

*HDL<sub>3</sub>, apolipoprotein A-I preparations and  $^{125}$ I-labelling* - HDL<sub>3</sub> were isolated from the plasma of normolipidemic donors as previously described [12]. ApoA-I was isolated from HDL<sub>3</sub> by ion-exchange chromatography as described [13].  $^{125}$ I-labeling of HDL<sub>3</sub> was performed by the N-bromosuccinimide method [14]. Specific radioactivity of  $^{125}$ I-ApoA-1 ranged from 600 to 1000 cpm/ng of protein.

*HDL Internalization assays* - HDL internalization assays were performed as previously described [3]. Briefly, HepG<sub>2</sub> cells were seeded on 24-well plates at 75,000 cells/well (~ 60 % confluence) and allowed to adhere and grow for 48h. Primary human hepatocytes were seeded at confluence and used no longer than a week after preparation. Hepatocytes were washed and equilibrated in serum free DMEM for 1 hour at 37°C; then were incubated for 5 min at 37°C with 75 µg/ml of  $^{125}$ I-HDL<sub>3</sub>. Cell were washed 3-times in serum-free DMEM, then dissociation of extracellular membrane-bound HDL was performed at 4°C in serum-free DMEM for 90 minutes. Cell were washed again 3-times in serum-free DMEM, then lysed in 0.5 ml NaOH 1M for cell radioactivity counting and protein concentration measurement. Results are expressed as the percent variation of internalization as compared to the

control (set at 0); the control corresponds to a mean value of ~ 200 ng of internalized HDL<sub>3</sub> per mg of cell proteins.

## Results

### *HepG<sub>2</sub> cells release ATP in the culture medium.*

We first determined whether HepG<sub>2</sub> cells were able to release ATP in the culture medium. After washing, HepG<sub>2</sub> cells were incubated in serum-free DMEM to assay for the extracellular ATP levels over time. HepG<sub>2</sub> cells released ATP immediately after medium change (Fig. 1A). Extracellular ATP concentration then decreased and stabilized over 1 hour of incubation to a value of  $76.5 \pm 6.5$  pmol ATP / mg cell proteins (~ 12nM). Same results were obtained when the experiment was performed in DMEM with 10% foetal bovine serum (Data not shown). No LDH activity could be detected in medium sample (data not shown), indicating that no cell lysis occurred during the time of the experiment.

To determine whether ATP release was dependent on the cell number, HepG<sub>2</sub> cells were seeded at various densities, allowed to grow for 48h before incubation in serum-free medium for 1 hour and ATP levels were measured. We observed a strong correlation between ATP concentration in the culture medium and the cell number (Fig. 1B).

Thus HepG<sub>2</sub> cells released ATP constitutively but the stabilization of extracellular ATP level over a short time (Fig. 1A) suggests a sharp regulation.

### *ADP increases ATP concentration in cell culture medium.*

In order to clarify the mechanism of ATP release, we determined whether HepG<sub>2</sub> cells were able of converting nucleotides to ATP. HepG<sub>2</sub> cells were incubated with various nucleotides and extracellular ATP concentration was measured. Figure 2A. shows that addition of ADP (10  $\mu$ M) to HepG<sub>2</sub> cells resulted in an increase of extracellular ATP content to  $5871 \pm 476$  pmol ATP / mg cell proteins (~ 1  $\mu$ M), which correspond to a ~100-fold increase of extracellular ATP content as compared to the control without ADP added (vehicle). The same concentration (10  $\mu$ M) of UDP, UTP, GDP, GTP or 2MeSADP (non-hydrolysable analogue of ADP) had no effect on

culture medium ATP concentration. Furthermore, ADP-induced ATP production strictly correlated with the added ADP concentration (Fig. 2B) and we could observe an ADP induced-ATP production (up to  $\sim 0.1 \mu\text{M}$ ), as low as  $1 \mu\text{M}$  ADP added. Thus ADP to ATP conversion may participate significantly to extracellular ATP generation.

*Contribution of nucleotide conversion enzymes to extracellular ADP to ATP conversion on hepatocytes.*

Two important reactions by which ADP can be converted to ATP have been identified at the cell surface of different cell types. These are adenylate kinase (AK) and ecto-nucleoside diphosphokinase (NDPK) activities [8, 15, 16]. AK catalyses the reaction  $2\text{ADP} \rightleftharpoons \text{ATP} + \text{AMP}$  and is inhibited by diadenosine pentaphosphate ( $\text{Ap}_5\text{A}$ ) [17]; NDPK catalyses a transphosphorylation reaction, transferring the  $\gamma$ -phosphate from a nucleoside triphosphate to a dinucleotide (e.g.  $\text{ADP} + \text{NTP} \rightleftharpoons \text{ATP} + \text{NDP}$ ). However these different enzymatic activities have never been clearly identified at the hepatocyte cell surface. Contrasting with these ADP to ATP conversion enzymes, the classical mitochondrial ATP synthase complex catalyzes the synthesis of ATP from ADP and inorganic phosphate using a proton-motive force ( $\text{ADP} + \text{P}_i \rightleftharpoons \text{ATP}$ ). We have previously shown that the ecto- $\text{F}_1\text{-ATPase}$  on hepatocytes could only hydrolyse ATP [2] whereas an ecto- $\text{F}_1\text{-ATPase}$  present on endothelial cell surface could both synthesize and hydrolyse ATP [18].

Using the ATP bioluminescence assay and HPLC analysis of radiolabelled nucleotides, we thus investigated the potential roles of cell surface AK, NDPK and  $\text{F}_1\text{-ATPase}$  activities in the extracellular conversion of ADP to ATP on HepG<sub>2</sub> cells and primary human hepatocytes.

By ATP bioluminescence assay, we first observed that the extracellular conversion of ADP to ATP was inhibited in the presence of  $\text{Ap}_5\text{A}$  ( $10 \mu\text{M}$ ) by  $65 \pm 3\%$  on HepG<sub>2</sub> cell and  $82 \pm 4\%$  on primary human hepatocytes (Fig. 3A), suggesting that most of the ATP generated at the hepatocyte cell surface was produced by adenylate kinase activity ( $2\text{ADP} \rightleftharpoons \text{ATP} + \text{AMP}$ ). Maximal inhibition of the ADP to ATP conversion occurred at  $10 \mu\text{M}$   $\text{Ap}_5\text{A}$ , as reported for other cell types [16] and higher concentrations of  $\text{Ap}_5\text{A}$  did not further inhibit ADP to ATP conversion (data not shown). In order to confirm that ADP was directly converted to ATP, HPLC analysis of extracellular [<sup>3</sup>H]-ADP metabolic products was performed on HepG<sub>2</sub> cells.



HAL author manuscript inserm-00142076, version 1

Incubation of HepG<sub>2</sub> cells with [<sup>3</sup>H]-ADP (10 μM) for 5 min induced [<sup>3</sup>H]-ATP production in the extracellular medium (Fig. 3B) and the generated [<sup>3</sup>H]-ATP decreased by 68 ± 3% when 10 μM Ap<sub>5</sub>A was added simultaneously with [<sup>3</sup>H]-ADP (Fig. 3C), confirming the role of AK activity in the ADP to ATP conversion at the cell surface of hepatocytes.

Secondly, ATP bioluminescence assay performed on HepG<sub>2</sub> cells and primary human hepatocytes indicated that the generation of extracellular ATP was higher upon incubation with both ADP (10 μM) and GTP (20 μM) as compared to ADP alone or GTP alone (Fig. 4A) and ATP production correlated with the GTP concentration (data not shown). This is an indication of the implication of a transphosphorylation reaction using GTP as a phosphate donor. Moreover, the response to ADP + GTP is reduced to that of ADP alone in the presence of an anti-NDPK antibody (no effect was observed with a non-immune rabbit IgG, not shown). Finally, we tested the inhibition of NDPK activity by high concentration of UDP as reported previously [19]. Indeed, ATP generation was strongly reduced when a high concentration (1mM) of UDP was added in combination with ADP + GTP (a higher concentration of UDP did not lead to further inhibition, not shown). Interestingly, ATP generation following ADP addition (without GTP) was decreased by ~ 50% with UDP (1mM) whereas anti-NDPK antibody had no effect on ATP level under the same conditions. Furthermore, HPLC analysis revealed a rapid formation of [<sup>3</sup>H]/[γ-<sup>32</sup>P]-double-labelled-ATP when HepG<sub>2</sub> cells were incubated for 5 min with both [<sup>3</sup>H]-ADP and [γ-<sup>32</sup>P]-GTP (Fig. 4B-C), confirming that the γ-<sup>32</sup>P of GTP had been transferred to the [<sup>3</sup>H]-ADP through a cell surface transphosphorylation NDPK activity. The presence of NDPK at the cell surface was confirmed by flow cytometry performed on intact HepG<sub>2</sub> cells using the anti-NDPK antibody (Fig. 4D). Altogether, these data strongly implicate NDPK in extracellular ATP generation, at least in the presence of extracellular tri-phosphate nucleotides, such as GTP.

ATP synthase uses Pi as a substrate for ATP production. However, ATP bioluminescence assay performed on HepG<sub>2</sub> cells and primary human hepatocytes showed that addition of inorganic phosphate (50 mM) to culture medium together with ADP did not further increase extracellular ATP production (Fig. 5A), as previously reported by Yegutkin et al. on human endothelial cells (HUVEC) [16]. In addition, incubation of HepG<sub>2</sub> cells with [<sup>3</sup>H]-ADP (10 μM), [<sup>32</sup>Pi] and unlabelled phosphate (10

mM) induced [<sup>3</sup>H]-ATP production in the extracellular medium (Fig. 5B) but the [<sup>3</sup>H]-ATP generated was not <sup>32</sup>P-labelled, (Fig. 5C), strongly indicating that extracellular ATP was not produced by the ecto-F<sub>1</sub>-ATPase activity, as previously reported [2]. Similar results were obtained at 1 min and 10 min incubation time (data not shown). As a confirmation, oligomycin (an inhibitor of mitochondrial ATP synthase [20]) did not reduce the extracellular ADP to ATP conversion as compared to the control (Fig. 5A). Altogether, these data indicate that the ecto-F<sub>1</sub>-ATPase is not involved in the extracellular ADP to ATP conversion on hepatocytes, a process which more likely implicates AK and NDPK activities.

#### *Contribution of NDPK and AK activities to HDL endocytosis by hepatocytes.*

The F<sub>1</sub>-ATPase-mediated HDL endocytosis pathway is strictly dependent on extracellular ADP level through the activation of the ADP-activated P2Y<sub>13</sub> receptor [2, 3]. Since the above results suggested that cell surface AK and NDPK activities were important in the extracellular metabolism of adenine nucleotides, we investigated the impact of these activities on HDL endocytosis by HepG<sub>2</sub> cells and primary human hepatocytes.

Addition of ATP + GDP in the HepG<sub>2</sub> cell medium to generate extracellular ADP through NDPK transphosphorylation activity ( $\text{ATP} + \text{GDP} \rightarrow \text{ADP} + \text{GTP}$ ) stimulated HDL endocytosis as efficiently as ADP addition (Fig 6A). This stimulation was abolished when cells were pre-incubated with the anti-NDPK antibody, confirming the NDPK was specifically involved under ATP + GDP treatment. Importantly, anti-NDPK antibody did not significantly modulate HDL endocytosis in the absence of exogenous nucleotides or in the presence of ADP only. This suggests that NDPK activity is unlikely to be involved in the basal level of HDL endocytosis. Similar results were obtained on primary human hepatocytes (Data not shown).

Strikingly, the AK inhibitor Ap<sub>5</sub>A stimulated HDL endocytosis by HepG<sub>2</sub> cells and primary human hepatocytes and this effect was additive to ADP stimulation (Fig 6B). This reveals that unlike NDPK, AK is constitutively active and consumes extracellular ADP ( $2\text{ADP} \rightarrow \text{ATP} + \text{AMP}$ ) thus inhibiting the ADP dependant P2Y<sub>13</sub>-mediated HDL endocytosis pathway. As previously reported [2], apoA-I stimulated HDL endocytosis up to ~30% (Fig 6B). Interestingly, the inhibition of AK activity by Ap<sub>5</sub>A enhances by ~50% the stimulation of HDL endocytosis by apoA-I (Fig 6B),

which suggests that AK activity counteracts the apoA-I effect by consuming the ADP generated through apoA-I interaction with the ecto-F<sub>1</sub>-ATPase. Finally, we previously observed that the F<sub>1</sub>-ATPase inhibitor IF<sub>1</sub> could inhibit both extracellular ADP generation and HDL endocytosis by HepG<sub>2</sub> cells [2]. Here, we observed that, in the presence of IF<sub>1</sub>, the AK inhibitor Ap<sub>5</sub>A could not up-regulate HDL endocytosis (Fig 6B). This is again a strong indication that, in basal conditions, AK mostly down-regulates HDL internalization through consuming the ADP generated by the ecto-F<sub>1</sub>-ATPase.

## Discussion

This work was designed to characterize the ecto-enzymatic activities that control ADP/ATP level on human hepatocytes and to determine their impact on the F<sub>1</sub>-ATPase/P2Y<sub>13</sub>-mediated-HDL endocytosis pathway [2, 3].

First, it is clear that the ecto-F<sub>1</sub>-ATPase substrate, i.e. ATP, is present at the surface of hepatocytes independently of cell lysis (Fig. 1). Indeed, mechanical perturbations induced by changing cell culture medium [21] trigger the release of ATP (Fig. 1A and [22]) that stabilizes after 1 hour. This basal extracellular ATP level most likely reflects a dynamic equilibrium in which the ATP metabolism at the cell surface of resting cells is balanced by constitutive ATP release. This constitutive ATP release might depend on ATP binding cassette (ABC) transporters [23], cell surface voltage-dependent anion channel VDAC [24], vesicle secretion [21, 25] or a network of mitochondria-associated-tubules [26].

Interestingly, ADP but not ATP can stimulate the ecto-F<sub>1</sub>-ATPase/P2Y<sub>13</sub>-mediated HDL endocytosis pathway [2, 3]. This indicates that the extracellular level of ATP is not limiting in this pathway, but the availability of ADP produced from ATP by the ecto-F<sub>1</sub>-ATPase is the limiting step of P2Y<sub>13</sub> activation. The concentration of extracellular ADP may be regulated to ecto-kinases activities that modulate extracellular ATP/ADP levels such as adenylate kinase (AK:  $2\text{ADP} \rightleftharpoons \text{ATP} + \text{AMP}$ ) or nucleoside diphosphokinase (NDPK:  $\text{ADP} + \text{NTP} \rightleftharpoons \text{ATP} + \text{NDP}$ ), which both have been reported at the cell surface of various cell types [6-8, 15, 16, 25]. Here, we clearly show that both AK and NDPK activities are also present at the cell surface of

hepatocytes. Indeed, we have observed that the conversion of exogenously added ADP to ATP occurs rapidly and increases in parallel with ADP concentration (Fig. 2A-B). The higher activity observed on primary hepatocytes as compared to HepG<sub>2</sub> cells may be attributed to an increased metabolism already described in primary cultures [27, 28]. This extracellular ADP to ATP conversion is mainly mediated by adenylate kinase as shown by the 68% and 82% inhibition observed in presence of the AK inhibitor Ap<sub>5</sub>A for HepG<sub>2</sub> cells and primary human hepatocytes, respectively. However, because Ap<sub>5</sub>A does not completely abolish the conversion of ADP to ATP, a small fraction of ATP may be produced by other ecto-nucleotide kinase enzymes. We also found that ecto-NDPK activity, which uses a  $\gamma$ -phosphate donor in the reaction  $ADP + NTP \rightleftharpoons ATP + NDP$ , can take part to extracellular ATP production when hepatocytes are incubated with both ADP and GTP. Indeed this extracellular ADP to ATP conversion increases in a dose-dependant manner with GTP concentration, can be reduced by NDPK antibody to the level obtained with ADP alone, and is strongly inhibited in presence of high concentration (1 mM) of UDP, as previously reported [19]. The last effect may be attributed to the ability of UDP to also counteract adenylate kinase activity in an alternative reaction  $ADP + UDP \rightleftharpoons AMP + UTP$  [29]. This hypothesis is supported by the fact that the anti-NDPK antibody strictly inhibits the GTP-induced ADP to ATP conversion and has no effect on ATP production when ADP is added alone (Fig. 4A). However, we do not totally exclude that NDPK may be activated by adding ADP alone as it has been reported that nucleoside triphosphate, particularly UTP, may be constitutively released by cells [30, 31].

Although we have previously reported that the ecto-ATP synthase (namely ecto-F<sub>1</sub>-ATPase) had only an ATP hydrolysis activity on hepatocytes [2], this ecto-enzyme was also found to both hydrolyse and synthesise ATP on keratinocytes [8] and endothelial cells [18]. We therefore investigated again whether an ecto-ATP synthase activity ( $ADP + P_i \rightleftharpoons ATP$ ) could be involved in the extracellular ADP to ATP conversion observed on hepatocytes. Contrasting with other studies reporting that oligomycin (a potent inhibitor of the mitochondrial F<sub>1</sub>F<sub>0</sub> ATP synthase by interaction with the F<sub>0</sub> subcomplex [20]), could partially inhibit extracellular ADP to ATP conversion [8], we do not observed in our system any effect of oligomycin on extracellular ATP production by hepatocytes. Furthermore, following incubation of

HepG<sub>2</sub> cells with [<sup>3</sup>H]-ADP and [<sup>32</sup>Pi], we unambiguously observe that the generated [<sup>3</sup>H]-ATP is not <sup>32</sup>P-labelled (Fig. 5B-C), suggesting a reaction different from that of the conventional ATP synthase, as previously reported by Yegutkin et al. on human endothelial cells [16]. Consistent with our data on hepatocytes, Yegutkin et al. have attributed this extracellular ATP production on endothelial cells to adenylate kinase and nucleoside diphosphokinase activities but not to ATP synthase activity [16]. Therefore, cell surface ATP synthesis observed on endothelial cells by other groups is probably not only due to the ATP synthase activity and need further investigations regarding other ecto-nucleotide kinases activities. However, it remains to be elucidated whether we are dealing with similar entities of the ATP synthase on the different cell types.

Thus, our data rule out the ability of the ecto-F<sub>1</sub>-ATPase to synthesize ATP on hepatocytes and show that the ADP to ATP conversion at the hepatocyte cell surface is mainly due to adenylate kinase and ecto-NDPK activities, the later being fully active when a co-substrate (e.g. GTP) is added.

This ADP to ATP conversion may be essential in the regulation of the F<sub>1</sub>-ATPase/P2Y<sub>13</sub>-mediated HDL endocytosis pathway. Indeed, our results reveal that ecto-NDPK activity can stimulate HDL endocytosis, only when the enzyme is activated with exogenous substrates (e.g. ATP + GDP) in order to generate extracellular ADP. By contrast, AK inhibitor Ap<sub>5</sub>A stimulates HDL endocytosis, suggesting that ecto-AK is constitutively active in consuming extracellular ADP. Moreover, because Ap<sub>5</sub>A does not further stimulate HDL endocytosis when the F<sub>1</sub>-ATPase activity is inhibited by IF<sub>1</sub>, it appears that most of the ADP constitutively generated by the ecto-F<sub>1</sub>-ATPase (ATP → ADP + Pi) is consumed by AK activity. Therefore, in the P2Y<sub>13</sub>-mediated pathway of HDL endocytosis, the availability of ADP to stimulate P2Y<sub>13</sub> and finally HDL uptake is a crucial point of regulation. It may depend on the balance between the constitutive AK activity that removes extracellular ADP and the ecto-F<sub>1</sub>-ATPase that synthesizes ADP. Activation of ADP synthesis by apoA-I unbalances the pathway and increases HDL endocytosis when required (Fig. 7).

This present work provides a better understanding of a cell surface nucleotide signal which is the initial step of the F<sub>1</sub>-ATPase/P2Y<sub>13</sub> pathway and will eventually lead to the endocytosis of the holo-HDL particles (protein plus lipid) through a low

affinity HDL binding site as previously described [2, 32, 33]. The identity of the low affinity receptor is still unknown and needs further investigations. Although Cla-1 (human ortholog of SR-BI) may be a good candidate [34], neither SR-BI/Cla-1 blocking antibody nor SR-BI/Cla-1 siRNA on HepG<sub>2</sub> cells could modify the basal or ADP-induced HDL uptake by HepG<sub>2</sub> cells ([1] and our unpublished data). Thus, it is more likely that the final step of this pathway, i.e uptake of the holo-HDL particles, occurs through an HDL-low affinity receptor different than SR-BI/Cla-1 (Fig. 7). This is consistent with other data suggesting that the selective lipid uptake, which is one of the main feature displayed by SR-BI [34], does not require HDL endocytosis [35, 36] and that the amount of HDL trafficking through the SR-BI-dependent retroendocytic pool is too small to support the SR-BI-mediated selective lipid uptake [37]).

In conclusion, this study brings up new insights in the F<sub>1</sub>-ATPase/P2Y<sub>13</sub>-mediated HDL endocytosis pathway by showing that modulating extracellular ADP level through the ecto-AK and ecto-F<sub>1</sub>-ATPase activities is a potential target for reverse cholesterol transport regulation. This opens up new strategies for the design of drugs able to increase HDL-cholesterol clearance, and subsequently the atheroprotective effect of these lipoproteins.

## REFERENCES

1. Martinez, L.O., Jacquet, S., Tercé, F., Collet, X., Perret, B. and Barbaras, R. (2004) New insight on the molecular mechanisms of high-density lipoprotein cellular interactions. *CMLS, Cell. Mol. Life Sci.* 61:001-018.
2. Martinez, L.O., Jacquet, S., Esteve, J.P., Rolland, C., Cabezon, E., Champagne, E., Pineau, T., Georgeaud, V., Walker, J.E., Terce, F., Collet, X., Perret, B. and Barbaras, R. (2003) Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. *Nature* 421:75-79.
3. Jacquet, S., Malaval, C., Martinez, L.O., Sak, K., Rolland, C., Perez, C., Nauze, M., Champagne, E., Terce, F., Gachet, C., Perret, B., Collet, X., Boeynaems, JM. and Barbaras, R. (2005) The nucleotide receptor P2Y(13) is a key regulator of hepatic High-Density Lipoprotein (HDL) endocytosis. *Cell Mol Life Sci*, 62:2508-2515.
4. Plesner, L. (1995) Ecto-ATPases: identities and functions. *Int Rev Cytol* 158:141-214.
5. Yegutkin, G.G., Henttinen, T., Samburski, S.S., Spychala, J. and Jalkanen, S. (2002) The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells. *Biochem J* 367:121-128.
6. Buckley, K.A., Golding, S.L., Rice, J.M., Dillon, J.P. and Gallagher, J.A. (2003) Release and interconversion of P2 receptor agonists by human osteoblast-like cells. *Faseb J* 17:1401-1410.
7. Donaldson, S.H., Picher, M. and Boucher, R.C. (2002) Secreted and cell-associated adenylate kinase and nucleoside diphosphokinase contribute to extracellular nucleotide metabolism on human airway surfaces. *Am J Respir Cell Mol Biol* 26:209-215.
8. Burrell, H.E., Wlodarski, B., Foster, B.J., Buckley, K.A., Sharpe, G.R., Quayle, J.M., Simpson, A.W. and Gallagher, J.A. (2005) Human keratinocytes release ATP and utilize three mechanisms for nucleotide interconversion at the cell surface. *J Biol Chem* 280:29667-29676.
9. Barbaras, R., Collet, X., Chap, H. and Perret, B. (1994) Specific binding of free apolipoprotein A-I to a high-affinity binding site on HepG2 cells: Characterization of two high-density lipoprotein sites. *Biochemistry* 33:2335-2340.
10. Ferrini, J.B., Ourlin, J.C., Pichard, L., Fabre, G. and Maurel, P. (1998) Human hepatocyte culture. *Methods Mol Biol* 107:341-352.
11. Payrastra, B., Missy, K., Giuriato, S., Bodin, S., Plantavid, M. and Gratacap, M. (2001) Phosphoinositides: key players in cell signalling, in time and space. *Cell Signal* 13:377-387.
12. Martinez, L.O., Georgeaud, V., Rolland, C., Collet, X., Tercé, F., Perret, B. and Barbaras, R. (2000) Characterization of Two High-Density Lipoprotein Binding Sites on Porcine Hepatocyte Plasma Membranes: Contribution of Scavenger Receptor Class B Type I (SR-BI) to the Low-Affinity Component. *Biochemistry* 39:1076-1082.
13. Mezdour, H., Clavey, V., Kora, I., Koffigan, M., Barkia, A. and Fruchart, J.C. (1987) Anion-exchange fast protein liquid chromatographic characterization and purification of apolipoproteins a-i a-ii c-i c-ii c-iii-0 c-iii-1 c-iii-2 and e from human plasma. *J. Chromatogr.* 414:35-46.
14. Sinn, H.J., Schrenk, H.H., Friedrich, E.A., Via, D.P. and Dresel, H.A. (1988) Radioiodination of proteins and lipoproteins using N-Bromosuccinimide as oxidizing agent. *Anal. Biochem.* 170:186-192.
15. Lazarowski, E.R., Homolya, L., Boucher, R.C. and Harden, T.K. (1997) Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists. *J Biol Chem* 272:20402-20407.

16. Yegutkin, G.G., Henttinen, T. and Jalkanen, S. (2001) Extracellular ATP formation on vascular endothelial cells is mediated by ecto-nucleotide kinase activities via phosphotransfer reactions. *Faseb J* 15:251-260.
17. Sinev, M.A., Sineva, E.V., Ittah, V. and Haas, E. (1996) Domain closure in adenylate kinase. *Biochemistry* 35:6425-6437.
18. Moser, T.L., Kenan, D.J., Ashley, T.A., Roy, J.A., Goodman, M.D., Misra, U.K., Cheek, D.J. and Pizzo, S.V. (2001) Endothelial cell surface F1-FO ATP synthase is active in ATP synthesis and is inhibited by angiostatin. *Proc Natl Acad Sci U S A* 98:6656-6661.
19. Lascu, I. and Gonin, P. (2000) The catalytic mechanism of nucleoside diphosphate kinases. *J Bioenerg Biomembr* 32:237-246.
20. Linnett, P.E. and Beechey, R.B. (1979) Inhibitors of the ATP synthetase system. *Methods Enzymol* 55:472-518.
21. Lazarowski, E.R., Boucher, R.C. and Harden, T.K. (2003) Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. *Mol Pharmacol* 64:785-795.
22. Schlosser, S.F., Burgstahler, A.D. and Nathanson, M.H. (1996) Isolated rat hepatocytes can signal to other hepatocytes and bile duct cells by release of nucleotides. *Proc Natl Acad Sci U S A* 93:9948-9953.
23. Roman, R.M., Wang, Y., Lidofsky, S.D., Feranchak, A.P., Lomri, N., Scharschmidt, B.F. and Fitz, J.G. (1997) Hepatocellular ATP-binding cassette protein expression enhances ATP release and autocrine regulation of cell volume. *J Biol Chem* 272:21970-21976.
24. Okada, S.F., O'Neal, W.K., Huang, P., Nicholas, R.A., Ostrowski, L.E., Craigen, W.J., Lazarowski, E.R. and Boucher, R.C. (2004) Voltage-dependent anion channel-1 (VDAC-1) contributes to ATP release and cell volume regulation in murine cells. *J Gen Physiol* 124:513-526.
25. Lazarowski, E.R., Boucher, R.C. and Harden, T.K. (2000) Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. *J Biol Chem* 275:31061-31068.
26. Beaudoin, A.R., Grondin, G. and Gendron, F.P. (1999) Immunolocalization of ATP diphosphohydrolase in pig and mouse brains, and sensory organs of the mouse. *Prog Brain Res* 120:387-395.
27. Wilkening, S., Stahl, F. and Bader, A. (2003) Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. *Drug Metab Dispos* 31:1035-1042.
28. Einarsson, C., Ellis, E., Abrahamsson, A., Ericzon, B.G., Bjorkhem, I. and Axelson, M. (2000) Bile acid formation in primary human hepatocytes. *World J Gastroenterol* 6:522-525.
29. Willemoes, M. and Kilstrup, M. (2005) Nucleoside triphosphate synthesis catalysed by adenylate kinase is ADP dependent. *Arch Biochem Biophys* 444:195-199.
30. Harden, T.K. and Lazarowski, E.R. (1999) Release of ATP and UTP from astrocytoma cells. *Prog Brain Res* 120:135-143.
31. Lazarowski, E.R. and Harden, T.K. (1999) Quantitation of extracellular UTP using a sensitive enzymatic assay. *Br J Pharmacol* 127:1272-1278.
32. Garcia, A., Barbaras, R., Collet, R., Bogyo, A., Chap, H. and Perret, B. (1996) High density lipoprotein3 (HDL3) receptor-dependent endocytosis pathway in a human hepatoma cell line (HepG2). *Biochemistry* 35:13064-13070.
33. Guendouzi, K., Collet, X., Perret, B., Chap, H. and Barbaras, R. (1998) Remnant high density lipoprotein2 particles produced by hepatic lipase display high-affinity binding and increased endocytosis into a human hepatoma cell line (HEPG2). *Biochemistry* 37:14974-14980.



34. Acton, S., Rigotti, A., Landschulz, K.T., Xu, S., Hobbs, H.H. and Krieger, M. (1996) Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. *Science* 271:518-520.
35. Nieland, T.J., Ehrlich, M., Krieger, M. and Kirchhausen, T. (2005) Endocytosis is not required for the selective lipid uptake mediated by murine SR-BI. *Biochim Biophys Acta* 1734:44-51.
36. Harder, C.J., Vassiliou, G., McBride, H.M. and McPherson, R. (2006) Hepatic SR-BI-mediated cholesteryl ester selective uptake occurs with unaltered efficiency in the absence of cellular energy. *J Lipid Res* 47:492-503.
37. Sun, B., Eckhardt, E.R., Shetty, S., van der Westhuyzen, D.R. and Webb, N.R. (2006) Quantitative analysis of SR-BI-dependent HDL retroendocytosis in hepatocytes and fibroblasts. *J Lipid Res* 47:1700-1713.

#### FOOTNOTE

We thank Dr. Bernard Payrastre (INSERM U563, Toulouse, France) for expert assistance with nucleotides HPLC analysis. Pr. Patrick Maurel (INSERM U128, Montpellier, France) for providing primary human hepatocytes. Pr. John Walker, Martin Montgomery and Mike Runswick (Dunn Human Nutrition Unit, Cambridge, UK) for helpful discussions. This study was supported by the Association Pour la Recherche sur le Cancer (ARC-3495) and the Alliance Program from Egide and British Council.

The abbreviations used are: ADP, Adenosine 5'-diphosphate; Ap<sub>5</sub>A, diadenosine pentaphosphate; ATP, Adenosine 5'-triphosphate; AK, adenylate kinase; apoA-I, apolipoprotein A-I; DMEM, Dulbecco's Modified Eagle's Medium; HDL, High Density Lipoprotein; IF<sub>1</sub>, inhibitor factor 1; NDPK, nucleoside diphosphokinase; PBS, Phosphate Buffered Saline.

#### FIGURE LEGENDS

**Fig. 1. ATP release from HepG<sub>2</sub> cells in function to medium change (A) and cell proteins concentration (B).** (A) HepG<sub>2</sub> cells were seeded on 24-well plates at 75,000 cells/well (~ 60% confluence) and allowed to adhere and grow for 48h. Complete medium was then removed, replaced with serum-free DMEM then extracellular medium was collected at each indicated period of time, and ATP was measured by luminometry. (B) HepG<sub>2</sub> cells were seeded at different densities from 25,000 to 150,000 cells/well then treated as in (A) except that cells were incubated for one hour with serum-free medium for stabilization before ATP content was measured. Data shown are mean ± S. E. (n = 3) and are representative of three separate experiments.

**Fig. 2. Effect of nucleotides on the ATP concentration of culture medium.** HepG<sub>2</sub> cells were seeded on 24-well plates at 75,000 cells/well (~ 60% confluence) and allowed to adhere and grow to confluence for 48h. (A) Cells were incubated in serum-free DMEM for one hour then nucleotides or nucleotide analogues (10 μM final concentration in DMEM) were added to HepG<sub>2</sub> cells for 1 min before samples of culture medium were taken, and the ATP content was measured by luciferin-luciferase assay. (B) Cells were incubated in serum-free DMEM for one hour then increasing concentrations of ADP (1-50 μM) were added to HepG<sub>2</sub> cells for 1 min

before samples of culture medium were collected and the ATP content was measured by luciferin-luciferase assay. Data shown are mean  $\pm$  S. E. (n = 4) and are representative of three separate experiments. \*\*, significance of  $p < 0.05$  in comparison with vehicle.

**Fig. 3. The conversion of ADP to ATP in culture medium of HepG2 cell and primary human hepatocytes is dependent to adenylate kinase activity.** (A) Confluent HepG<sub>2</sub> cells or primary human hepatocytes were washed and preincubated for 1h in 0.5 ml of serum free medium then the adenylate kinase inhibitor Ap<sub>5</sub>A (10  $\mu$ M) was added for 10 min. ADP (10  $\mu$ M) was then introduced for 1 min and cell culture medium samples were collected for ATP measurement by luciferin-luciferase assay. Data shown are mean  $\pm$  S. E. (n = 4) and are representative of three separate experiments. (B and C) HPLC analysis of metabolic products of ADP at the HepG<sub>2</sub> cell surface. Cells were washed and preincubated for 1h in 0.5 ml of serum free medium and subsequently incubated for 5 min in the presence of [<sup>3</sup>H]ADP (1  $\mu$ Ci) alone (Panel B) or simultaneously with Ap<sub>5</sub>A (10  $\mu$ M) (Panel C). Samples of cell medium were then taken and nucleotides were separated by HPLC and [<sup>3</sup>H] species detection was performed. The retention times for various standards are indicated with *arrows*. Data are representative of two separate experiments.

**Fig. 4. The conversion of ADP to ATP in culture medium of HepG2 cell and primary human hepatocytes is dependant to NDPK activity.** (A) ADP and other nucleotides were introduced alone or simultaneously to confluent HepG<sub>2</sub> cells or primary human hepatocytes for 1 min then cell culture medium samples were collected and ATP was measured by luciferin-luciferase assay. Where not shown, ADP was used at 10  $\mu$ M, GTP at 20 $\mu$ M and UDP at 1mM. When used, NDPK antibody (100  $\mu$ g/ml) was pre-incubated for 30 min prior to addition of nucleotides. Data shown are mean  $\pm$  S. E. (n = 4) and are representative of two separate experiments. (B and C) HPLC analysis of metabolic products of ADP at the HepG<sub>2</sub> cell surface. Cells were washed and preincubated for 1h in 0.5 ml of serum free medium and subsequently incubated for 5 min in the presence of [<sup>3</sup>H]ADP (1  $\mu$ Ci) +  $\gamma$ [<sup>32</sup>P]GTP (1  $\mu$ Ci). Samples of cell medium were then taken and nucleotides were separated by HPLC and dual detection was performed (Panel B: [<sup>3</sup>H] species detection; Panel C: [<sup>32</sup>P] species detection). The retention times for various standards are indicated with *arrows*. (D) NDPK is present at the cell surface of hepatocytes. Flow cytometry on intact HepG<sub>2</sub> cells. Undashed histogram represents cells incubated with an antibody against the NDPK enzyme. Dashed histogram represents cells incubated with the isotypic control antibody.

**Fig. 5. Ecto-F<sub>1</sub>-ATPase activity is not involved in the conversion of ADP to ATP in culture medium of HepG<sub>2</sub> cell and primary human hepatocytes.** (A) ADP (10  $\mu$ M) was introduced alone or simultaneously with inorganic phosphate (50mM) to confluent HepG<sub>2</sub> cells or primary human hepatocytes for 1 min then cell culture medium samples were collected and ATP was measured by luciferin-luciferase assay. When used, oligomycin (10  $\mu$ g/ml) was pre-incubated for 10 min prior to addition of ADP (10  $\mu$ M). Because oligomycin was dissolved in ethanol, an ethanol (1/100) control was performed. Data shown are mean  $\pm$  S. E. (n = 3) and are representative of three separate experiments. (B and C) HPLC analysis of metabolic products of ADP at the HepG<sub>2</sub> cell surface. Cells were washed and preincubated for 1h in 0.5 ml of serum free medium and subsequently incubated for 5 min in the presence of [<sup>3</sup>H]ADP (1  $\mu$ Ci) + <sup>32</sup>Pi (0.5  $\mu$ Ci). Samples of cell medium were then taken and species were separated by HPLC and dual detection was performed (Panel B: [<sup>3</sup>H] species detection; Panel C: [<sup>32</sup>P] species detection). The retention times for various standards are indicated with *arrows*.

**Fig. 6. Effect modulators of NDPK and adenylate kinase activity on HDL<sub>3</sub> internalisation by HepG<sub>2</sub> cells.** Cells were incubated for 5 min at 37°C with 75  $\mu$ g/ml <sup>125</sup>I-HDL<sub>3</sub> and different

modulators then treated as described in “Experimental Procedures”. Where not shown, nucleotides and IF<sub>1</sub> were used at 100 nM, Ap<sub>5</sub>A was used at 1 μM, apoA-I at 10 μg/ml and anti-NDPK antibody (NDPK Ab) at 100 μg/ml.

**Fig. 1. Model of the F<sub>1</sub>-ATPase/P2Y<sub>13</sub>-mediated HDL endocytosis by hepatocytes.** Cell surface adenylate kinase (AK) activity down-regulates an SR-BI-independent holo-HDL particles endocytosis pathway by consuming the ADP generated by the ecto-F<sub>1</sub>-ATPase. This process depends on the balance between the AK activity that removes extracellular ADP and the ecto-F<sub>1</sub>-ATPase that synthesizes ADP. Activation of ADP synthesis by apoA-I unbalances the pathway and increases HDL endocytosis when required. CE: cholesterol ester.